A Platform Trial for Gram Negative Bloodstream Infections
BALANCE+: A Platform Trial for Gram Negative Bloodstream Infections
Sunnybrook Health Sciences Centre
2,500 participants
Apr 24, 2024
INTERVENTIONAL
Conditions
Summary
BALANCE+ is a perpetual multiple domain randomized controlled platform trial to evaluate various treatment strategies for Gram-negative bloodstream infections (GN BSIs). Each domain addresses critical questions in the management of GN BSIs, aiming to refine treatment strategies, enhance patient outcomes, and reduce antimicrobial resistance. The initial vanguard pilot RCT (NCT05893147) started on 29 August 2023 and has successfully completed the pilot phase on 24-Apr-2024. All patients enrolled in the vanguard phase are part of the main platform trial.
Eligibility
Inclusion Criteria11
- admitted to a participating hospital
- positive blood culture with Gram negative (GN) bacterium
- \- included in BALANCE+ platform
- included in BALANCE+ platform
- initially treated with intravenous antibiotics, but clinical team transitioning patient to oral/enteral antibiotic within 7 days of starting treatment
- included in BALANCE+ platform
- has an indwelling central vascular catheter that was already in place within the 48-hour period before the onset of bloodstream infection (i.e. is not a new catheter placed within 48 hours of the onset of infection)
- included in BALANCE+ platform
- positive blood culture with GN bacterium, of the following species: i. Serratia spp. ii Morganella spp. iii Providencia spp. iv Proteus spp. other than P.mirabilis
- organism is susceptible to ceftriaxone
- \- included in BALANCE+ platform
Exclusion Criteria51
- patient's goals of care are for palliation with no active treatment
- moribund patient, not expected to survive > 72 hours
- previously enrolled in the platform trial
- not eligible for any domain at the time of screening
- De-escalation versus no de-escalation domain
- receiving an empiric antibiotic regimen at the time of blood culture finalization to which the GN pathogen(s) are not sensitive
- arbapenem-non-susceptible
- no de-escalation option due to any or all of:
- antimicrobial resistance
- allergies
- medical contraindications
- drug-drug interaction risk
- other relevant reason
- patients with a suspected or proven polymicrobial source of infection
- > 24 hours since index blood culture susceptibility results finalization
- Beta-lactam versus non-beta-lactam oral/enteral treatment domain
- enrolled in an arm of another BALANCE+ platform domain which limits the use of oral/enteral therapy:
- no-de-escalation arm (patients in the no de-escalation arm cannot be randomized into this domain unless they are ready for discharge home, in which case de-escalation is allowable to oral agents at discharge)
- no non-beta-lactam options due to any or all of:
- resistance
- allergies
- medical contraindications
- drug-interaction risk
- other relevant reason
- no beta-lactam options due to any or all of:
- resistance
- allergies
- medical contraindications
- drug-interaction risk
- other relevant reason
- pregnancy
- already received >24 hours of oral antibiotics after index blood culture finalization
- Central vascular catheter replacement domain
- patient has no ongoing need for a central vascular catheter
- patient has definite indication for central vascular catheter removal
- ongoing septic shock with definite/probable line source
- concomitant S. aureus bacteremia
- concomitant candidemia
- local suppurative signs (severe redness, warmth, pain, swelling or fluctuance/collection) necessitating catheter removal, or other clinical evidence of infected line (e.g. imaging/echocardiographic findings)
- Low-risk AmpC domain
- severe allergy to beta-lactams (e.g., type 4 hypersensitivity reaction or DRESS)
- baseline phenotypic non-susceptiblity to ceftriaxone
- more than 1 calendar day beyond availability of susceptibility results
- Follow up blood culture domain
- patient died or discharged from hospital prior to day 4
- blood culture already collected by the treating team at day 4±1
- >5 days since index positive blood culture collection
- definite indication for repeat blood culture testing
- concomitant S. aureus bacteremia
- concomitant Candidemia
- clinical suspicion for infective endocarditis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital. De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol).
Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime. Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.
Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed.
Cephalosporin (ceftriaxone) at standard doses Carbapenem (Meropenem or Ertapenem) at standard doses
Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria. No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria
Locations(39)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06537609